Histone deacetylase (HDAC) inhibition using vorinostat (SAHA) [suberoylanilide hydroxamic acid] after autologous hematopoietic stem cell transplantation for high risk lymphoma

Trial Profile

Histone deacetylase (HDAC) inhibition using vorinostat (SAHA) [suberoylanilide hydroxamic acid] after autologous hematopoietic stem cell transplantation for high risk lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2015

At a glance

  • Drugs Vorinostat (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; T cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Feb 2012 Actual patient number is 23 according to ClinicalTrials.gov.
    • 21 Feb 2012 Company (Merck) added as trial sponsor as reported by ClinicalTrials.gov.
    • 21 Feb 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top